Clinuvel Pharmaceuticals Ltd
CUV•Health Care•Biotechnology•Last updated: Dec 25
About
Clinuvel Pharmaceuticals Ltd is a global biopharmaceutical company focused on developing and delivering treatments for patients with severe genetic and skin disorders. The company operates primarily through its Pharmaceuticals Division, which develops and commercializes its lead product, SCENESSE, for the treatment of erythropoietic protoporphyria (EPP). Clinuvel also explores the use of its technology in other indications such as vitiligo and DNA repair.
Share Price Chart
Company Details
- Sector
- Health Care
- Industry
- Biotechnology
- ASX Code
- CUV
Related Shares
Investor Resources
Should you buy Clinuvel Pharmaceuticals Ltd right now?
While CUV looks interesting right now, our experts have just put together a full report on the ultimate ASX investment portfolio - designed for growth and passive income.
Join the Rask weekly investment newsletter to get the names, right now